Illumina and Kindstar Global Announce Strategic Collaboration

Illumina, Inc. and Kindstar Global  announced they are entering into a strategic collaboration whereby Kindstar will validate and implement molecular assays in their laboratories, leveraging Illumina’s TruSightTM content sets, Infinium® Dx CytoSNP-12 assay and NuPCRTM reagents. The collaboration will enable Kindstar to expand its esoteric and specialty testing services offerings within its network of more than 3,300 hospitals across China.

“Kindstar’s adoption of Illumina’s TruSight technology across its extensive network in China speaks to the breadth and depth of content in this innovative portfolio,” said Matt Posard, Senior Vice President and General Manager of Illumina’s Translational and Consumer Genomics business. “Next-generation sequencing is enabling a dramatic improvement in both coverage and accuracy for molecular diagnostics, and we look forward to additional partnerships that continue to drive this improvement forward.”

“Kindstar is excited to offer services in China based on Illumina’s products including the TruSight content sets,” said Dr. Shiang Huang, Founder and CEO of Kindstar. “Leveraging Illumina’s technology will enable us to offer the highest quality and most specialized diagnostics.”